Using e-Technologies to Maximize Physical Activity After Cancer Treatment

November 4, 2026 updated by: University of Florida

Using e-Technologies to Maximize Physical Activity After Cancer Treatment: The eMPACT Trial

The Cancer Exercise app (CEA) is designed to promote physical activity among cancer survivors. The proposed randomized controlled clinical trial will investigate, in adults who have completed cancer treatment, the effects of a 12-week home-based exercise program, delivered using CEA, on physical activity levels. Participants will be randomized into one of two groups: (1) CEA or (2) Usual Care.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

750

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 to 85 years of age
  • Diagnosed with stage I-III cancer
  • Completed all primary cancer treatments (e.g., surgery, radiation, chemotherapy) at least 6 months prior to enrollment. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, immunotherapy, and bisphosphonates are allowed within 6 months of study enrolment and during study participation.
  • Own a smartphone with data plan or access to WiFi (Apple or Android)
  • Medical clearance provided or no medical clearance needed based on exercise preparticipation screening.

Exclusion Criteria:

  • consistently engage in >300 min/week of moderate-intensity physical activity or 150 min/week of vigorous-intensity physical activity in the past 3 months
  • receiving or scheduled to receive surgery or radiation during study participation
  • have stage IV metastatic cancer or evidence of cancer recurrence
  • have multiple myeloma
  • have received bone marrow or hematopoietic stem cell transplant within past year
  • are unable to walk without support or have severe weakness or balance problems that limit safe participation in exercise
  • contraindications to participate in unsupervised exercise
  • are pregnant
  • unable to read, speak and understand English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cancer Exercise app group
Behavioral: Cancer Exercise App

Use of Cancer Exercise app to increase physical activity levels among cancer survivors.
No Intervention: Usual Care group

Participants assigned to Usual Care group will receive no intervention. After completing the post-intervention assessments, they will be provided with information on how to download and use the Cancer exercise app.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in moderate to vigorous physical activity from pre- to post-intervention
Time Frame: Baseline and following the 12-week intervention

Moderate to vigorous physical activity will be assessed using the International Physical Activity Questionnaire, a well-validated and reproducible questionnaire for use among cancer survivors
Baseline and following the 12-week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Florida

Investigators

  • Principal Investigator: Demetra Christou, PhD, University of Florida
  • Principal Investigator: Danielle Jake-Schoffman, PhD, University of Florida

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 16, 2026

Primary Completion (Estimated)

May 1, 2028

Study Completion (Estimated)

May 1, 2028

Study Registration Dates

First Submitted

April 10, 2026

First Submitted That Met QC Criteria

April 10, 2026

First Posted (Actual)

April 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

November 4, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB202501619

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe